Drug intelligence / Profile preview

BLK-IN-2

Development stage: Preclinical
Modality: Small Molecules

Overview

BLK-IN-2 (also known as compound 25) is a potent, selective, and irreversible small molecule inhibitor of B-lymphoid tyrosine kinase (BLK) with an IC50 of 5.9 nM. It also inhibits Bruton's tyrosine kinase (BTK) with an IC50 of 202.0 nM. Developed by researchers at Peking University, BLK-IN-2 exhibits potent antiproliferative activities against several B-cell lymphoma cell lines and has demonstrated high sensitivity in BLK-high leukemic cells, particularly in the TCF3-PBX1 translocated subtype of B-cell acute lymphoblastic leukemia (B-ALL).

Other names: compound 25compound25compound-25

Targets

BLK (B lymphoid tyrosine kinase)

Beyond the preview

Go deeper on BLK-IN-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLK-IN-2.